A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC

Conclusion In patients with advanced non-squamous NSCLC, the feasible dose of apatinib given with standard-dose pemetrexed and carboplatin was 500  mg/day schedule 2/1. The schedule was generally well tolerated and demonstrated promising clinical benefit in NSCLC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

Conclusion: Higher pretreatment RDW levels were demonstrated to be associated with poor clinical outcome in male LSCC patients and might be novel markers for patient stratification in LSCC management. Introduction Laryngeal cancer is one of the most common cancers of the head and neck, of which the estimated crude incidence and mortality rates in China were 1.86/100,000 and 1.01/100,000, respectively (1). This disease has a male predominance with a male-to-female ratio of 20 to 30:1 in China (2). The most commonly observed histological type of laryngeal cancer is laryngeal squamous cell cancer (LSCC), accounting for ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Rationale: Lung cancer is the leading cause of cancer-associated deaths all over the world. Although the prognosis of lung cancer has improved over the past decade due to progression in surgical techniques and systematic treatments, the patients with advanced disease still suffer poor survival. There are no standard treatment strategies for patients who have failed to respond to at least 2 lines of chemotherapy in non-small cell lung cancer (NSCLC). Apatinib, one of the latest small-molecule oral anti-angiogenesis targeted agents developed first in China, has shown remarkable anti-tumor efficacy in a variety of solid tum...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Conclusion: Response to acalabrutinib remained consistent during long-term (>24-month) follow-up, including high response rates, median PFS of 19.5 months, and a median OS that has not yet been reached, confirming efficacy in patients with relapsed/refractory MCL. The AE profile was largely similar to earlier reporting, with limited additional safety events observed with an additional year of follow-up.DisclosuresWang: Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Dava Oncology: Honoraria; AstraZeneca: Consultancy, Research Funding; Pharmacyclics: Honoraria, R...
Source: Blood - Category: Hematology Authors: Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Poster II Source Type: research
Conclusion: Apatinib has promising antitumor activity and manageable toxicity profile in patients with advanced NSCLC that failed prior chemotherapy or EGFR-TKIs. This result needs to be confirmed through the ongoing Phase III clinical trial.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research
Copyright © 2018 Cognizant Communication Corporation. Oncol Res. 2018 Jun 21;: Authors: Tang J, Li XY, Liang JB, Wu, Peng L, Li X Abstract Apatinib is an oral TKI with anti-angiogenesis properties, and it is currently approved for the treatment of advanced gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell lung cancer (NSCLC). Since the combination of chemotherapy and an anti-angiogenesis agent has been shown to be feasible strategy in NSCLC, it is conceivable that a similar approach combining apatinib with chemotherapy may yield clinical...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
Conclusion: Apatinib exhibited modest activity and acceptable toxicity for advanced NSCLC after the failure of chemotherapy or other targeted therapy.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsApatinib is effective and well tolerated in patients with advanced NSCLC, even at a dosage of 500 mg qd, and might offer a new option for the treatment of such patients with brain metastases.
Source: Asia-Pacific Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
CONCLUSION: Combining foretinib and erlotinib demonstrated response in unselected advanced NSCLC but also incremental toxicity. Future development will require molecular patient selection. PMID: 28706139 [PubMed - as supplied by publisher]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
An 88-year-old female with a past medical history of a hypertension, atrial fibrillation, and stage IV non-small-cell lung cancer (NSCLC) presented to the emergency department with sudden onset left eye blindness and abdominal pain. She was noted to have worsening anemia and heme-occult positive stools; however, abdominal imaging did not indicate any acute pathology. Given her baseline poor functional status, the patient was not a candidate for aggressive interventions. One week before presentation, the patient had received a first dose of pembrolizumab, 200  mg intravenous (i.v.) infusion, which was to be administe...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsIn resected stage I NSCLC patients adjuvant 400  mg/day pazopanib but not 800 mg/day was feasible, although possibly infra-therapeutic and failed to improve relapse-free survival.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Alimta | Cancer | Cancer & Oncology | Drugs & Pharmacology | Hematology | Hypertension | Investigational New Drugs | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Study | Toxicology